[go: up one dir, main page]

TW332201B - 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives - Google Patents

1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Info

Publication number
TW332201B
TW332201B TW085103447A TW85103447A TW332201B TW 332201 B TW332201 B TW 332201B TW 085103447 A TW085103447 A TW 085103447A TW 85103447 A TW85103447 A TW 85103447A TW 332201 B TW332201 B TW 332201B
Authority
TW
Taiwan
Prior art keywords
alkyl
hydrogen
phenyl
substituted
formula
Prior art date
Application number
TW085103447A
Other languages
English (en)
Inventor
Jean Edgard Freyne Eddy
S M Diels Gaston
I Andres-Gil Jose
J Fernandez-Gadea Francisco
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of TW332201B publication Critical patent/TW332201B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW085103447A 1995-04-06 1996-03-22 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives TW332201B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200868 1995-04-06
EP95202898 1995-10-26

Publications (1)

Publication Number Publication Date
TW332201B true TW332201B (en) 1998-05-21

Family

ID=26139205

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085103447A TW332201B (en) 1995-04-06 1996-03-22 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Country Status (26)

Country Link
US (2) US5994376A (zh)
EP (1) EP0819122B1 (zh)
JP (1) JP4562101B2 (zh)
KR (1) KR100406628B1 (zh)
CN (1) CN1068591C (zh)
AR (1) AR002732A1 (zh)
AT (1) ATE214052T1 (zh)
AU (1) AU702947B2 (zh)
CA (1) CA2216653C (zh)
CY (1) CY2328B1 (zh)
CZ (1) CZ293127B6 (zh)
DE (1) DE69619661T2 (zh)
DK (1) DK0819122T3 (zh)
ES (1) ES2174064T3 (zh)
HR (1) HRP960155A2 (zh)
HU (1) HU223324B1 (zh)
IL (1) IL117807A (zh)
MX (1) MX9707652A (zh)
MY (1) MY119254A (zh)
NO (1) NO314339B1 (zh)
NZ (1) NZ304877A (zh)
PL (1) PL187375B1 (zh)
PT (1) PT819122E (zh)
SI (1) SI0819122T1 (zh)
TW (1) TW332201B (zh)
WO (1) WO1996031485A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TR199900732T2 (xx) * 1996-10-02 1999-08-23 Janssen Pharmaceutica N.V. PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
JP2002508001A (ja) 1997-07-10 2002-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｉｌ−５インヒビターとしての６−アザウラシル誘導体
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
IL138745A0 (en) * 1998-04-01 2001-10-31 Janssen Pharmaceutica Nv Pde iv inhibiting pyridine derivatives
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
CA2328250A1 (en) * 1998-04-14 1999-10-21 Cornelia Jutta Forster Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
ES2198980T3 (es) * 1998-11-23 2004-02-01 Janssen Pharmaceutica N.V. Derivados de 6-azauralico inhibidores de il-5.
DE69936396T2 (de) 1998-12-18 2008-06-19 Janssen Pharmaceutica N.V. Il-5 hemmende 6-uracilderivate
WO2002022123A1 (en) * 2000-09-13 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
MXPA03010679A (es) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
AU2005260328B2 (en) * 2004-07-05 2009-10-01 Dong Wha Pharmaceutical Co., Ltd. Composition for the prevention and treatment of allergic inflammatory disease
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007085357A1 (en) * 2006-01-30 2007-08-02 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
EP2155226A4 (en) * 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF
KR101512548B1 (ko) * 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL285394A (zh) * 1961-11-17
US3184060A (en) 1963-02-13 1965-05-18 Owens Illinois Glass Co Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials
AU9030691A (en) * 1990-11-06 1992-05-26 Smithkline Beecham Corporation Imidazolidinone compounds
CA2400368A1 (en) * 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
TW263495B (zh) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
DE69619661T2 (de) 2002-10-31
MX9707652A (es) 1997-11-29
SI0819122T1 (en) 2002-06-30
HK1007880A1 (zh) 1999-04-30
KR100406628B1 (ko) 2004-05-31
DK0819122T3 (da) 2002-07-01
PL322654A1 (en) 1998-02-16
HUP9801575A3 (en) 1999-03-01
NZ304877A (en) 1999-06-29
MY119254A (en) 2005-04-30
CA2216653A1 (en) 1996-10-10
CY2328B1 (en) 2004-02-06
JPH11503136A (ja) 1999-03-23
CZ314997A3 (cs) 1998-12-16
CN1181072A (zh) 1998-05-06
US6403805B1 (en) 2002-06-11
CN1068591C (zh) 2001-07-18
NO314339B1 (no) 2003-03-10
CZ293127B6 (cs) 2004-02-18
HU223324B1 (hu) 2004-06-28
IL117807A0 (en) 1996-08-04
AR002732A1 (es) 1998-04-29
AU702947B2 (en) 1999-03-11
NO974602L (no) 1997-10-06
DE69619661D1 (de) 2002-04-11
AU5275596A (en) 1996-10-23
CA2216653C (en) 2009-05-26
PL187375B1 (pl) 2004-06-30
ATE214052T1 (de) 2002-03-15
PT819122E (pt) 2002-08-30
IL117807A (en) 2001-06-14
HUP9801575A2 (hu) 1999-01-28
US5994376A (en) 1999-11-30
EP0819122A1 (en) 1998-01-21
JP4562101B2 (ja) 2010-10-13
HRP960155A2 (en) 1997-10-31
US20020068830A1 (en) 2002-06-06
EP0819122B1 (en) 2002-03-06
ES2174064T3 (es) 2002-11-01
WO1996031485A1 (en) 1996-10-10
KR19980703449A (ko) 1998-11-05
NO974602D0 (no) 1997-10-06

Similar Documents

Publication Publication Date Title
TW332201B (en) 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
US4587258A (en) Angiotensin-converting enzyme inhibitors
US4831157A (en) Preparation of angiotensin-converting enzyme inhibitors
AU4437896A (en) Piperidine derivatives having tachykinin antagonist activity
ATE273958T1 (de) Heterocyclische verbindungen als h+-atpasen
TR199800849T2 (xx) Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
DE69410121D1 (en) Dihydro pyrazolopyrrole
DE69634045D1 (de) Antithrombotische diamine
IL209653A0 (en) Peptide derivatives
DE69510928D1 (de) Heterocyclische verbindungen, ihre herstellung und verwendung
ATE291018T1 (de) Pyrazol verbindungen und ihre verwendung
MXPA04006033A (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina.
ATE269865T1 (de) Pyrazolo(3,4-g)chinoxaline als pdgf-rezeptor protein tyrosin-kinase inhibitoren
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
DK0674515T3 (da) Anvendelse af carbostyrilderivater til fremstilling af et medikament til inhibering af interleukin-8
ATE265851T1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
MXPA05006271A (es) Metodo para el tratamiento de desordenes del movimiento usando derivados de acido barbiturico.
CA2202904A1 (en) Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
MA26796A1 (fr) Derive d'aminotetraline pour la therapie des maladies cardiovasculaires.
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent